Michel is CEO and Board member of Theradiag, a company specialized in biotherapy monitoring and diagnostic.
Prior to joining Theradiag, Michel was executive VP of Neovacs and Flamel Technologies, both biotech companies listed on Alternext and Nasdaq respectively, CEO of Carmat, an innovative company developing a total artificial heart and listed on Alternext and co-founded by Truffle Capital, Senior Vice President of the Aventis Group, one of the leading pharmaceutical companies in the world, and Senior Vice President and CFO of Sanofi Pasteur, a world leader in vaccines.
Michel is also a Director of France Biotech, the French association of entrepreneurs in the biotech sector, and of Carmat and Neovacs.
Michel graduated from EM Lyon and is a Certfied Public Accountant. Chevalier de l’ordre national du Mérite.